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Abstract
Chronic administration of L-DOPA, the first-line treatment of dystonic symptoms in childhood or in Parkinson’s disease, often
leads to the development of abnormal involuntary movements (AIMs), which represent an important clinical problem. Although
it is known that Riluzole attenuates L-DOPA-induced AIMs, the molecular mechanisms underlying this effect are not understood.
Therefore, we studied the behavior and performed RNA sequencing of the striatum in three groups of rats that all received a
unilateral lesion with 6-hydroxydopamine in their medial forebrain bundle, followed by the administration of saline, L-DOPA, or
L-DOPA combined with Riluzole. First, we provide evidence that Riluzole attenuates AIMs in this rat model. Subsequently,
analysis of the transcriptomics data revealed that Riluzole is predicted to reduce the activity of CREB1, a transcription factor that
regulates the expression of multiple proteins that interact in a molecular landscape involved in apoptosis. Although this mech-
anism underlying the beneficial effect of Riluzole on AIMs needs to be confirmed, it provides clues towards novel or existing
compounds for the treatment of AIMs that modulate the activity of CREB1 and, hence, its downstream targets.
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Introduction
Chronic administration of the dopamine precursor L-DOPA—
the first-line treatment of dystonic symptoms manifesting in
childhood or in Parkinson’s disease (PD) [1]—often leads to
the development of so-called abnormal involuntary move-
ments (AIMs). In humans, L-DOPA-induced AIMs are re-
ferred to as L-DOPA-induced dyskinesia (LID) [2], which
represents an important clinical problem as approximately
90% of PD patients develop LID within 10 years of starting
L-DOPA treatment. As a result, the prescription of L-DOPA to
PD patients is often delayed to minimize the risk of develop-
ing LID [3].
The pathogenic mechanisms underlying AIMs and clinical
LID are still largely unclear. Literature evidence indicates that
chronic L-DOPA administration affects multiple neurotrans-
mitter systems [4–6], but mainly the dopaminergic system,
i.e., L-DOPA activates striatal dopamine 1 receptors (D1Rs),
resulting in the overstimulation of the Bdirect^ nigrostriatal
pathway [7, 8]. In turn, this hypersensitivity of D1Rs in striatal
neurons triggers a number of downstream signaling cascades
involving—among others—cyclic AMP (cAMP)-activated
protein kinase A (PKA) [9, 10], the phosphatase inhibitor
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DARPP-32 [10, 11], and the ERK1 and ERK2 (ERK1/2) ki-
nases [12, 13] that are subsequently implicated in the devel-
opment of LID throughmodulating gene expression and func-
tion [14, 15]. In this respect, previous transcriptomic and
methylation studies in rodent models indeed indicate that
AIMs/LID are associated with aberrant gene expression
through transcription factors, such as CREB1, proteins from
the AP-1 complex [9, 16] (such as FOSB) [17], and GADD45
family proteins [17].
Recently, Riluzole has been suggested as a candidate drug
to treat AIMs/LID. Indeed, several studies on rodent models
have provided evidence for the efficacy of Riluzole in the
management of AIMs [2, 18, 19]. As for human studies,
Riluzole showed anti-dyskinetic effects without affecting
the anti-parkinsonian actionofL-DOPAina small pilot study
[20], but it was ineffective in another clinical trial [21].
Riluzole essentially has anti-glutamatergic properties—
including effects on glutamate release, uptake, and receptor
signaling [22–25], and it protects against glutamate-induced
activation of kinases, such as ERK1/2 [26]. More specifical-
ly, although Riluzole has properties resembling those of a
competitiveNMDA receptor antagonist, its effects on reduc-
ing glutamatergic neurotransmission are more indirect [27].
Indeed, the anti-glutamatergic effects of Riluzole could re-
sult from a reduction of glutamate release from synapses
through an inhibition of voltage-gated sodium channels
[28], a reduction in the post-synaptic calcium influx mediat-
ed by P/Q-type calcium channels [29], a reduction in gluta-
mine import into synapses (with glutamine being a precursor
for the releasable glutamate pool) [30], or through interfering
with the size of the readily releasable glutamate pool [31].
Further, animal model studies suggest that Riluzole is not
selective for glutamate but also reduces the release of acetyl-
choline, dopamine, and, to a lesser extent, serotonin through
mechanisms independent of glutamate receptors [32].
However, a detailed understanding of the molecular mecha-
nism(s) underlying the protective effect of Riluzole on
AIMs/LID is essentially lacking.
In this study, we aimed to elucidate the molecular mecha-
nisms underlying the beneficial effect of Riluzole on AIMs.
Therefore, we studied the behavior and performed RNA se-
quencing of the striatum, followed by gene expression analy-
sis and comparison in three groups of rats. All rats received a
unilateral lesion with 6-hydroxydopamine (6-OHDA) in their
medial forebrain bundle (MFB)—resulting in striatal dopami-
nergic hypersensitivity—after which they were administered
saline, L-DOPA (which constitutes a rat model of AIMs), or
L-DOPA combined with Riluzole. We found that Riluzole
attenuates L-DOPA-induced AIMs in the rat model. In addi-
tion, further analysis indicated that Riluzole is predicted to
reduce the activity of the transcription factor CREB1, the
key hub in a landscape of interacting proteins that are involved
in regulating neuronal apoptosis.
Methods
Animals and Ethical Approvals
Juvenile male Wistar rats (RjHan:WI) were used in this study.
Rats were obtained from our provider (Janvier, Le Genest-St
Isle, France) at the age of 14 days together with their mothers.
In total, 5 juvenile rats and a mother were housed together
with free access to food and water, under a 12-h light and dark
cycle in temperature- and humidity-controlled rooms. All an-
imals were habituated to their housing conditions for one
week. Animal housing and experiments were approved by
the appropriate institutional governmental agency
(Regierungspräsidium Tübingen, Germany) and performed
in an AAALAC (Association for Assessment and
Accreditation of Laboratory Animal Care International)-
accredited facility, following the European Convention for
Animal Care and Use of Laboratory Animals.
Stereotaxic Surgery
After 1 week of habituation at post-natal day (PND) 21
(n = 48), the rats were separated from their mothers and
underwent stereotaxic surgery with 6-hydroxydopamine
hydrobromide (6-OHDA). Further details are provided in
the Supplementary methods.
Animal Treatment
Two weeks after stereotaxic surgery, the rats were randomly
allocated to 4 groups (n = 12 animals per group) associated to
different pharmacological treatments, at the same conditions:
the first group was chronically administered (6 times in
2 weeks, intra-peritoneally (i.p.)) with a solution of L-DOPA
methyl ester hydrochloride and benserazide (Sigma-Aldrich
Chemie GmbH, Germany) in saline (6/15 mg/kg, i.p.). The
second group (control) was administered with saline. The
third group was chronically administered (6 times in 2 weeks)
with Riluzole (Sigma-Aldrich Chemie GmbH, Germany) dis-
solved in 1% Tween (6 mg/kg, i.p.) and L-DOPA/benserazide
(6/15 mg/kg, i.p.). The fourth (6-OHDA-lesioned) group
followed the same procedure as group 1 and was used to
verify the presence of the lesion by quantification of dopamine
(DA) levels in striatal tissue using high-performance liquid
chromatography (HPLC) coupled to electrochemical detec-
tion (ECD).
Phenotype Scoring
Four weeks after surgery (PND 49), the rats were administered
their treatment and were individually observed for 1 min every
20 min. Abnormal involuntary movements (AIMs) of the
limb, mouth, and body axis were assessed according to the
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widely used AIMs rating scale [33]. Briefly, each type of
movement was scored on a scale from 0 to 4 (0 = absent;
1 = occasional; 2 = frequent; 3 = continuous but interrupted
by sensory distraction; 4 = continuous, severe, not interrupted
by sensory distraction). The sum of the independent scores of
each body part per time point gave the total AIMs score.
Animal Sacrifice and Sample Extraction
At PND 53, rats were sacrificed 2 h after the administration of
a final treatment. Rats were anesthetized for 60 s in 5%
isoflurane and quickly decapitated by guillotine. Following
brain removal, lesioned and unlesioned striata were extracted,
snapped-frozen in liquid nitrogen, and stored at − 80 °C. A
schema of the experimental procedure is outlined in Fig. 1.
Striatal DA Determination Through HPLC
DA levels in 12 6-OHDA-lesioned striata compared to their
contralateral controls were quantified using HPLC coupled to
ECD. Further details are provided in the Supplementary
methods.
Behavioral Testing: Statistical Analysis
Time-course data were analyzed for statistical significance
using two-way analysis of variance (ANOVA) followed by
Tukey’s multiple comparison test. Dopaminergic HPLC quan-
tification in lesioned versus unlesioned striata was analyzed
using a Wilcoxon matched-pairs signed-ranked test.
RNA Sequencing and Data Analysis
Total RNAwas extracted from striatum tissue from 8 animals
from each group using the QiagenAllPrep Kit (Qiagen,
Hamburg, Germany), according to the manufacturer’s instruc-
tions. RNAwas further quantified using the NanoDrop 1000
Spectrophotometer and Bioanalyzer 2100 (Agilent). Samples
with RIN value above 8.0 were used for transcriptome analy-
sis. The sequencing library preparation was done using 200 ng
of total RNA input with the TrueSeq RNA Sample Prep Kit
v3-Set B (RS-122-2002, Illumina Inc., San Diego, CA) pro-
ducing a 275 bp fragment including adapters in average size.
In the final step before sequencing, 12 individual libraries
were normalized and pooled together using the adapter indices
supplied by the manufacturer. Pooled libraries were clustered
on the cBot Instrument from Illumina using the TruSeq SR
Cluster Kit v3—cBot—HS (GD-401-3001, Illumina Inc., San
Diego, CA), and sequencing was then performed as 78 bp,
single reads and 7 bases index read on an Illumina
HiSeq3000 instrument using the TruSeq SBS Kit HS—v3
(50-cycle) (FC-401-3002, Illumina Inc., San Diego, CA).
Reads were aligned to the rat genome using the STAR
Aligner v2.5.2a [34] with corresponding Ensembl 84 refer-
ence genome (http://www.ensembl.org). Sequenced read
quality was checked with FastQC v0.11.2 (http://www.
bioinformatics.babraham.ac.uk/projects/fastqc/), and
alignment quality metrics were calculated using RNASeQC
v1.18 [35]. Following read alignment, duplication rates of the
RNA sequencing samples were computed with bamUtil v1.0.
11 to mark duplicate reads and the dupRadar v1.4
Bioconductor R package for assessment [36]. Gene
expression profiles were quantified using Cufflinks software
version 2.2.1 [37] and the feature counts software package
Fig. 1 Schematic diagram of the
protocol employed including the
time course of the experiment and
the different assays that were used
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[38]. Transcripts with at least 10 reads in 8 samples were
retained and further used to identify differentially expressed
genes between the following three experimental groups:
saline, L-DOPA, and L-DOPA + Riluzole. Statistical
analyses were performed using R (www.r-project.org) and
the Bioconductor package ([39], www.bioconductor.org)
limma-voom [40]. The Benjamini-Hochberg’s method was
used to correct for multiple testing, and only protein-coding
genes with adjusted p value < 0.01, independent of magnitude
of change, were considered as differentially expressed and
used in the subsequent analyses. The Venn diagram of the
final sets of significantly differentially expressed genes for
the two comparisons was built with Venny [41]. To assess
the effect of Riluzole on L-DOPA-regulated genes, we also
looked at the overlap between the genes regulated by L-DOPA
(L-DOPAvs. saline, comparison 1) and the genes regulated by
Riluzole in the L-DOPA model (L-DOPA + Riluzole vs. L-
DOPA, comparison 2). To quantify this overlap, we used the
hypergeometric distribution test [42]:
p xj n;M ;Nð Þ ¼
M
x
 
N−M
n−x
 
N
n
 
This test calculates the chance of observing exactly x
overlapping genes from a total of n differentially
expressed genes by Riluzole in the L-DOPA model, with
a total of M genes that were differentially expressed by L-
DOPA and a total of N genes detected with RNAseq. The
total number of unique genes detected with RNAseq (N)
consists of genes detected in both comparisons, irrespec-
tive of their FC or expression p value. For all compari-
sons, only protein-coding genes were considered. To de-
termine the correlation between the fold changes for the
overlapping genes in the two comparisons, we created a
scatter plot and calculated the Spearman’s correlation co-
efficient using the ggscatter function in R package ggpubr.
Upstream Regulator and Gene Enrichment Analyses
Using Ingenuity Pathway Analysis (IPA; Qiagen Inc.), we
performed upstream regulator and gene enrichment anal-
yses. Based on the differentially expressed genes, IPA
generates a list of Bupstream regulators,^ i.e., proteins or
compounds that are able to explain observed gene expres-
sion changes in the input dataset. For each upstream reg-
ulator, IPA calculates a p value of overlap (measuring the
statistical significance of the overlap between the dataset
genes and all genes that are regulated by the upstream
regulator) and a z score (reflecting the inhibition or acti-
vation of the upstream regulator-dependent effects on
target gene expression). We selected the major upstream
regulator with the best z score and p value of overlap for
the two comparisons—i.e., L-DOPA vs. saline and L-
DOPA + Riluzole vs. L-DOPA—and used the target genes
of this upstream regulator for further analyses. In the gene
enrichment analysis, IPA assigns genes and their corre-
sponding mRNAs/proteins to functional (sub)-categories,
i.e., Bcanonical pathways^ and Bbiofunctions,^ with the
latter including Bdiseases and disorders^ and Bmolecular
and cellular functions.^
Molecular Landscape Building
Following the upstream regulator and enrichment analy-
ses, we searched the literature for the functions and inter-
actions of all proteins encoded by the target genes of the
major upstream regulator and expressed in the opposite
direction in the two comparisons, i.e., L-DOPA vs. saline
and L-DOPA + Riluzole vs. L-DOPA. First, we used the
UniProt Knowledge Base ([43], http://www.uniprot.org)
to gather basic information on the functions of all target
genes and their encoded proteins. Subsequently and
starting with the interactions reported by IPA, we used
PubMed (http://www.ncbi.nlm.nih.gov/pubmed) to search
for all functional, experimental evidence-based interac-
tions between the proteins. Based on all gathered infor-
mation, we generated a protein interaction landscape. The
figure depicting this landscape was made using the draw-
ing program Serif DrawPlus version 4.0 (www.serif.com).
qPCR Validation of Selected CREB1 Targets
To provide an additional validation of the RNA sequenc-
ing data, we performed qPCR to assess and compare the
mRNA expression levels of 10 randomly chosen CREB1
targets in each of the samples of the groups investigated
in this study (saline, L-DOPA, L-DOPA + Riluzole). RNA
from the same samples used for the RNA sequencing was
reverse-transcribed to cDNA using the RT2 First-Strand
Kit (Qiagen, Cat. number 330404) according to the man-
ufacturer’s instructions. Three-step qPCR (95 °C for
10 min, followed by 40 two-step cycles at 95 °C for
15 s and 60 °C for 30 s, and the generation of melting
curves from 70 to 95 °C; Rotor-Gene Q 1000, Qiagen)
was performed using RT2 SYBR Green ROX™ qPCR
Mastermix (Qiagen, Cat. number 330521) and RT2
qPCR primer Assays provided by Qiagen. The house-
keeping genes Bcap29 and Cdkn1b were used as reference
for normalization of gene expression, and a Student’s t
test was used to assess statistical significance. The full
list of primers is specified in Supplementary Table 1.
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Table 1 CREB1 target genes that were significantly differentially expressed in comparisons L-DOPAvs. saline and L-DOPA+Riluzole vs. L-DOPAwith
the corresponding fold changes (FDR-corrected p value < 0.01). The genes in bold encode proteins that are included in our molecular landscape (Fig. 3)
CREB1 target gene Description L-DOPA vs. saline L-DOPA +Riluzole vs. L-DOPA
Arc Activity regulated cytoskeleton-associated protein 6.41 − 2.99
Atf3 Activating transcription factor 3 10.98 − 6.06
Bag3 BCL2-associated athanogene 3 1.80 − 1.73
Ccnd3 Cyclin D3 1.22 − 1.31
Cdc37 Cell division cycle 37 1.27 − 1.28
Cdk19 Cyclin-dependent kinase 19 − 1.22 1.18
Cdkn1a Cyclin-dependent kinase inhibitor 1A 4.09 − 2.57
Crem cAMP-responsive element modulator 1.73 − 1.52
Crh Corticotropin-releasing hormone 6.32 − 4.62
Csrnp1 Cysteine- and serine-rich nuclear protein 1 3.06 − 1.88
Dusp14 Dual specificity phosphatase 14 4.15 − 2.44
Egr4 Early growth response 4 10.01 − 4.16
Ehd4 EH domain containing 4 1.30 − 1.30
Fgf13 Fibroblast growth factor 13 − 1.29 1.26
Fos Fos proto-oncogene, AP-1 transcription factor subunit 12.99 − 4.94
Fosb FosB proto-oncogene, AP-1 transcription factor subunit 17.17 − 4.96
Frmd6 FERM domain containing 6 2.16 − 1.59
Gaa Glucosidase alpha, acid 1.46 − 1.34
Gadd45b Growth arrest and DNA damage-inducible beta 3.43 − 1.76
Gadd45g Growth arrest and DNA damage-inducible gamma 4.59 − 2.92
Gpr3 G protein-coupled receptor 3 8.19 − 3.95
Hspa5 Heat-shock protein family A (Hsp70) member 5 1.64 − 1.41
Id1 Inhibitor of DNA binding 1, HLH protein 1.44 − 1.57
Igsf9b Immunoglobulin superfamily member 9B 1.93 − 1.63
Inhba Inhibin beta A subunit 5.76 − 3.41
Irs2 Insulin receptor substrate 2 6.01 − 3.00
Jun Jun proto-oncogene, AP-1 transcription factor subunit 2.45 − 1.70
Junb JunB proto-oncogene, AP-1 transcription factor subunit 7.83 − 3.28
Klf4 Kruppel like factor 4 2.00 − 1.60
Lmo1 LIM domain only 1 1.25 − 1.23
Midn Midnolin 2.52 − 2.34
Ndufv1 NADH:ubiquinone oxidoreductase core subunit V1 1.19 − 1.21
Nfil3 Nuclear factor, interleukin 3 regulated 2.08 − 1.51
Npas4 Neuronal PAS domain protein 4 5.50 − 5.07
Nptx2 Neuronal pentraxin 2 4.96 − 2.70
Npy Neuropeptide Y 1.72 − 2.23
Nr4a1 Nuclear receptor subfamily 4 group A member 1 4.27 − 2.15
Nr4a3 Nuclear receptor subfamily 4 group A member 3 10.26 − 4.16
Nrgn Neurogranin 1.56 − 1.36
Pdxk Pyridoxal kinase 1.93 − 1.69
Pdyn Prodynorphin 2.50 − 1.75
Per1 Period circadian clock 1 2.18 − 1.87
Pim3 Pim-3 proto-oncogene, serine/threonine kinase 1.41 − 1.39
Plat Plasminogen activator, tissue type 1.47 − 1.48
Ptgs2 Prostaglandin-endoperoxide synthase 2 5.15 − 3.08
Pvr Poliovirus receptor 2.84 − 2.34
Rem2 RRAD- and GEM-like GTPase 2 5.42 − 2.82
Rheb Ras homolog enriched in brain 1.49 − 1.18
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Results
Assessment of Striatal DA Depletion by Assaying Its
Content
To confirm the degree of dopaminergic denervation in the unilat-
eral 6-OHDA-lesioned rats, total (intracellular and extracellular)
dopamine (DA) tissue content in the ipsilateral (lesioned) and
contralateral (control) striatum relative to the lesion was assayed
by HPLC coupled to ECD. 6-OHDA lesion induced a marked
decrease (76%) in DA concentration in the ipsilateral striatum
compared with the contralateral side (Supplementary Fig. 1).
Behavioral Effects: Induction of AIMs by L-DOPA
in 6-OHDA-Lesioned Rats and Their Mitigation
by Riluzole
Intra-MFB 6-OHDA lesion plus 2 weeks of chronic L-DOPA
exposure induced strong abnormal involuntary movements
(p < 0.001), while 6-OHDA-lesioned rats given saline showed
no abnormal motor phenotype. Chronic treatment with
Riluzole together with L-DOPA was associated with fewer
AIMs than L-DOPA alone (p < 0.001), as shown in Fig. 2.
RNA Sequencing Data Analysis and Upstream
Regulator/Gene Enrichment Analyses
Transcriptomic analysis was performed on the mRNA from
the RNA samples isolated from the (lesioned) striatum of sa-
line-, L-DOPA-, and L-DOPA +Riluzole-treated rats 2 h after
the administration of a final injection. This allowed examina-
tion of the striatal mRNA gene expression profiles (and as-
sessment of the counteracting effect of Riluzole) at the peak of
L-DOPA effectiveness. The statistically significant differ-
ences in gene expression levels in striatum of L-DOPA- vs.
saline-treated rats (comparison 1) and in L-DOPA + Riluzole-
vs. L-DOPA-treated rats (comparison 2) are shown in
Supplementary Data file 1.
Among the differentially expressed genes, 667 were differ-
entially expressed only in comparison 1 and 1200 genes were
differentially expressed only in comparison 2. Further, 465
genes were overlapping in that they were differentially
expressed in both comparisons (Supplementary Fig. 2), and
all of these genes were differentially expressed in the opposite
direction in the two comparisons (i.e., genes that were upreg-
ulated by chronic L-DOPA treatment were downregulated by
Riluzole co-administration and vice versa). The significance
of the overlap in differentially expressed genes was calculated
by using the hypergeometric distribution test, which showed
that the overlap is much greater than would be expected based
on random gene selection (p value = 1.01E−142).
As indicated in Supplementary Table 2, cAMP-responsive
element binding protein 1 (CREB1) is the top upstream regulator
of both the genes that were differentially expressed in compari-
son 1 and comparison 2, and in these comparisons, CREB1 is
predicted to be activated and inhibited, respectively. In addition,
CREB1 is the top upstream regulator of the 465 overlapping
differentially expressed genes (see previous texts) and there is a
highly significant, negative correlation (r = − 0.91, p value =
2.2E−16) between the fold changes for these genes—including
Table 1 (continued)
CREB1 target gene Description L-DOPA vs. saline L-DOPA +Riluzole vs. L-DOPA
Scg2 Secretogranin II 2.90 − 1.69
Sema7a Semaphorin 7A (John Milton Hagen blood group) 1.30 − 1.27
Sertad1 SERTA domain containing 1 2.83 − 1.74
Sh3kbp1 SH3 domain containing kinase binding protein 1 − 1.15 1.13
Sik1 Salt-inducible kinase 1 3.10 − 2.08
Slc32a1 Solute carrier family 32 member 1 1.79 − 1.52
Srxn1 Sulfiredoxin 1 6.08 − 3.28
Stat3 Signal transducer and activator of transcription 3 1.13 − 1.13
Tac1 Tachykinin precursor 1 2.82 − 1.92
Vegfa Vascular endothelial growth factor A 1.33 − 1.30
Fig. 2 Induction of AIMs by L-DOPA in 6-OHDA-lesioned rats and their
mitigation by Riluzole. Data shown as mean ± S.E.M. AIMs scores.
Significant differences between the saline and L-DOPA-treated groups
are indicated as **p < 0.01 and ****p < 0.001 and between the L-
DOPA and L-DOPA +Riluzole-treated groups as ####p < 0.001
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the 58 direct CREB1 target genes—in the two comparisons
(Supplementary Fig. 3).
Furthermore, gene enrichment analysis (Supplementary
Table 3) revealed that the three sets of differentially expressed
genes are significantly enriched for a number of Bdiseases and
disorders^ categories, including Bepileptic seizure^ (enriched in
all three gene sets), as well as Bdisorder of basal ganglia^ and
Bneuromuscular disease^ (enriched in the genes from compari-
son 1). In addition, the gene sets are enriched for multiple
Bmolecular and cellular functions^ categories, such as Bcell
death/apoptosis^ and Bexpression/transcription of RNA^
(enriched in all three gene sets) as well as Bdevelopment of
neurons^ (enriched in the genes from comparison 2).
Molecular Landscape of CREB1 Targets
Subsequently, we further investigated the CREB1-mediated
molecular mechanisms implicated in the counteractive effect
of Riluzole on L-DOPA-induced changes in gene expression.
Therefore, the set of 58 CREB1 target genes that were regu-
lated in the opposite direction by L-DOPA and Riluzole
(Table 1) was studied in more detail, and enrichment analysis
of these 58 overlapping genes showed that Bepileptic seizure^
and Bapoptosis^ are the most significantly enriched Bdiseases
and disorders^ and Bmolecular and cellular functions^ catego-
ries, respectively (Supplementary Table 4).
The proteins encoded by 43 of the 58 CREB1 target genes
could be placed into a molecular landscape (Fig. 3). In the sup-
plementary materials (Supplementary materials), all the protein
interactions in this landscape are described in great detail. That
being said, we here give a succinct description of the main pro-
cesses and signaling cascades in the landscape. Importantly, as the
main signaling Bhub^ in the landscape, CREB1 is a transcription
factor that regulates the expression of many target genes involved
in neuronal processes, such as neuronal survival, differentiation,
and development. Further, there are three main landscape
Fig. 3 The molecular landscape is located in a neuron and shows the functional interactions between proteins encoded by 43 of the 58 CREB1 target
genes regulated in the opposite direction by L-DOPA and after Riluzole co-administration in our AIMs model
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cascades in the nucleus. First, the AP-1 transcription factor
complex—consisting of JUN, FOS, JUNB, and FOSB—binds
and interacts with CREB1 and is regulated by and regulates the
expression of a number of other landscape proteins, e.g., ATF3
and CREM. In addition, a complex of two functionally related
transcription factors—NR4A1 and NR4A3, which regulate neu-
ronal survival downstream of CREB1—interacts with the AP-1
complex and is regulated by extracellular molecules that are in-
volved in (dopaminergic) apoptosis, such as CRH, TAC1, and
VEGFA. The third important signaling cascade in the nucleus
centers around the transcription factors of the GADD45 family
that regulate the neuronal stress response and apoptosis and in-
teract with other transcription factors like CCND3 and
CDKN1A. Further, most other landscape proteins interact with
two proteins/protein complexes that regulate neuronal apoptosis
and can be found both in the nucleus and cytoplasm, i.e., ERK1/2
and the adaptor protein STAT3. The signaling cascades depen-
dent on ERK1/2 and STAT3 are in turn modulated by a number
of extracellular proteins—e.g., FGF13, PLAT, and SCG2—and
cytoplasmic regulators—e.g., DUSP14, HSPA5, and IRS2—
with prominent roles in neuronal function and survival.
qPCR Validation of Selected CREB1 Targets
To provide an additional validation of the RNA sequencing
data, we performed qPCR to assess and compare the mRNA
expression levels of 10 selected CREB1 targets. In
Supplementary Fig. 4, the expression differences are shown
for both comparisons (L-DOPA vs. saline and L-DOPA +
Riluzole vs. L-DOPA). As we were able to validate 8 of the
10 tested mRNA expression differences and the two other
differences were not statistically significant but still in the
right direction, we submit that the RNA sequencing data, in
general, and the expression data for the CREB1 targets, in
particular, indeed reflect true expression changes.
Discussion
In the current study, we ascertained that 6-OHDA-lesioned
rats treated with L-DOPA demonstrate clear AIMs and this
is counteracted by chronic exposure to Riluzole, a drug that
has already been shown to have some effect on attenuating
AIMs in previous studies. Our experiments revealed that
Riluzole induces mRNA expression changes in the rat stria-
tum that are tightly linked to the occurrence of L-DOPA-
induced AIMs.
Our findings point towards the regulation of apoptosis as a
keymolecular mechanism underlying both the effect of chron-
ic L-DOPA administration—with the accompanying AIMs—
and the Brebalancing^ effect of Riluzole, leading to a reduc-
tion of AIMs. In general terms, the landscape that we built
Fig. 4 Putative mechanisms of
how Riluzole could counteract
CREB1-mediated gene expres-
sion by decreasing the activity of
CREB1. Firstly, through a num-
ber of mechanisms, Riluzole re-
duces glutamatergic neurotrans-
mission, which includes less glu-
tamate binding to post-synaptic
NMDA glutamate receptors. As a
result, NMDA-mediated ERK1/2
signaling and the subsequent ac-
tivation of CREB1 are also re-
duced. Secondly, Riluzole could
inhibit PKC, a kinase that posi-
tively regulates NMDA receptors
and activates CREB1 (directly or
through activating ERK1/2),
leading to a reduced CREB1 ac-
tivity. The key players in this
mechanism—L-DOPA, NMDA
glutamate receptors, the kinases
ERK1/2 and PKC, and CREB1
itself—are shown
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based on the CREB1 targets that were expressed in the oppo-
site direction in the AIMs model and after Riluzole adminis-
tration suggests that chronic administration of L-DOPA tilts
the neuronal survival/apoptosis balance towards increased
survival (and, hence, less apoptosis). Conversely, Riluzole
administration leads to a reversal of this balance towards less
survival and more apoptosis. Indeed, most of the landscape
genes encode proteins that have anti-apoptotic properties, and
these genes are upregulated after chronic L-DOPA adminis-
tration, an effect that is counteracted by Riluzole.
Mechanistically, as derived from the upstream regulator anal-
ysis, the effect of Riluzole is mediated through decreasing the
activation of CREB1, i.e., CREB1 (and, hence, the regulation
of its downstream targets) is predicted to be activated upon
exposure to L-DOPA and inhibited after adding Riluzole.
CREB1 acts as a functional Bgo-between^ between cytoplas-
mic kinase/enzyme signaling cascades and nuclear regulation
of gene expression. More specifically, CREB1 is known to be
activated through phosphorylation by kinases, such as ERK1/
2 [44] and protein kinase C (PKC) [45] (see subsequent texts),
which in turn leads to reduced neuronal apoptosis through the
upregulation of anti-apoptotic gene expression by activated
CREB1 [46]. In addition, L-DOPA administration to 6-
OHDA-lesioned rats was found to markedly increase
CREB1 phosphorylation in striatal neurons [47, 48], and, in-
terestingly, a very recent study showed that Riluzole reduces
neuronal CREB1 phosphorylation [49].
As for how Riluzole would decrease CREB1 activity,
there are some clues from the literature. Taken together
with our results, these literature findings have led us to
propose a putative molecular mechanism—shown in Fig.
4—through which Riluzole could decrease CREB1 activ-
ity, modulate apoptosis, and ultimately reduce AIMs.
First, and as pointed out previously, Riluzole mainly ex-
erts anti-glutamatergic effects which, through a number of
mechanisms [27–31], lead to reduced glutamatergic neu-
rotransmission. When activated by glutamate, post-
synaptic NMDA receptors activate ERK1/2, kinases with
an important role in our landscape that subsequently phos-
phorylate—and, hence, activate—CREB1 [44]. These da-
ta imply that through its anti-glutamatergic effects,
Riluzole would decrease CREB1 activity by reducing
NMDA receptor-induced ERK1/2 signaling. Second,
Riluzole is a potent intracellular inhibitor of PKC [50], a
kinase that positively regulates NMDA receptor function
[51] and phosphorylates/activates CREB1, either directly
or through activating ERK1/2 [45]. Although not shown
in Fig. 4, a recent paper reported that Riluzole also re-
duces presynaptic glutamatergic vesicle recycling and,
hence, the size of the readily releaseable glutamate pool
through inhibiting PKC [31]. Further, it is interesting that
glutamate-induced activation of CREB1 is (partially)
blocked by inhibiting ERK1/2 with U0126 [52], a
compound that, as opposed to CREB1, is predicted to be
inhibited after exposure to L-DOPA and activated by
adding Riluzole (see Supplementary Table 2).
Although our study yielded interesting findings, it has
some limitations. First, while chronic L-DOPA administration
is thought to be the main contributor to the AIMs phenotype
through its effect on striatal projection neurons—i.e., through
promoting dopamine receptor hypersensitivity in these
neurons—lesioning with 6-OHDA affects dopaminergic as
well as noradrenergic neurons. As such, a contribution of 6-
OHDA-induced noradrenergic denervation to the AIMs phe-
notype cannot be excluded. In addition, although our results
indicate that the effect of Riluzole on reducing AIMs is medi-
ated through lowering CREB1 activity, further studies are
needed to confirm that Riluzole (in)directly decreases
CREB1 activity through reducing its phosphorylation. In this
respect, it is interesting to note that the literature provides
some corroborating evidence that phosphorylation-
dependent CREB1 activation is indeed an important contrib-
uting factor to the development of AIMs. For example,
psychostimulants, such as amphetamines and cocaine, and
other drugs, such as the anti-psychotic aripiprazole—that are
a l l known to i nduce AIMs [53–55 ]—p romo t e
phosphorylation-dependent CREB1 activation in (striatal)
neurons [56–58]. Therefore, in addition to confirming the ef-
fect of Riluzole, future studies could test other (novel or
existing) drugs for their positive effect on AIMs (and LID)
through decreasing CREB1 activity.
In conclusion, we have demonstrated that Riluzole at-
tenuates AIMs in 6-OHDA-lesioned rats that were chron-
ically treated with L-DOPA. In addition, RNA sequencing
analysis revealed that Riluzole reverses the expression
direction of genes regulating mainly pro-apoptotic pro-
cesses, downstream of activated CREB1. This molecular
mechanism underlying the beneficial effect of Riluzole
needs to be confirmed in future studies and can be lever-
aged to design AIMs/LID treatment studies using novel
and/or existing compounds.
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